Cantor Fitzgerald analysts maintain their Buy rating on Omeros Corporation
Following promising OMS721 data in kidney disorders, Omeros added that the drug improved TMA blood markers in 3/5 hematopoietic stem cell transplantation (HSCT) patients.
“Platelet count and haptoglobin levels were increased, while mean LDH levels have decreased from baseline. These results were as robust as those reported last year from two aHUS patients, lending confidence to the assumption of broad utility of OMS721 in TMAs,” analyst Elemer Piros wrote in a note.
As such, Omeros could pursue three distinct indications with OMS721 in pivotal trials beginning in the fourth quarter. Piros expects the company’s deep pipeline to deliver steady news flow over the next 12-24 months.
At time of writing, shares of Omeros rose 5.89 percent to $8.06. Piros has a price target of $21.
|Jun 2016||Cantor Fitzgerald||Initiates Coverage on||Buy|
|Apr 2016||Roth Capital||Terminates||Buy|
|Aug 2015||Roth Capital||Initiates Coverage on||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.